Drug Utilisation Sub-Committee outcome statement

18 March 2020 - The outcome statement from the February 2020 Drug Utilisation Sub-Committee meeting is now available. ...

Read more →

HHS Secretary Alex Azar expresses hope in biosimilar uptake, notes positive momentum

11 March 2020 - HHS Secretary Alex Azar discussed the future of biosimilars in the United States and the actions taken ...

Read more →

PhRMA: federal biosimilar payment policies are having a positive effect

4 March 2020 - Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discusses recent policy changes ...

Read more →

Lyrica, a drug linked to depression and anxiety, now the top pain medication on the PBS

18 February 2020 - Lucy Pallot had never experienced the lows of depression and anxiety until she started taking pregabalin. ...

Read more →

How protected classes in Medicare Part D influence U.S. drug sales, utilisation, and price

13 February 2020 - When the Medicare Part D prescription drug benefit was implemented in 2006, six drug classes were designated ...

Read more →

Refocusing medication prior authorisation on its intended purpose

3 February 2020 - During the 1980s, prospective utilisation review programs deployed by US health plans focused on screening the ...

Read more →

Copayment incentive increased medication use and reduced spending among indigenous Australians after 2010

3 February 2020 - Australian health policy has prioritised efforts to close the ten-year life expectancy gap between indigenous and non-indigenous ...

Read more →

CMS payment policy plays role in biosimilar uptake

30 January 2020 - How does CMS payment policy for Medicare, Medicaid, and 340B hospitals affect biosimilar uptake? A speaker ...

Read more →

Achieving cost savings with biosimilars will require new strategies, authors say

20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...

Read more →

Report on the collection of under co-payment data 2018-19

17 December 2019 - The report on the collection of under co-payment data 2018-19 is now available. ...

Read more →

Lamotrigine NPPA change

17 December 2019 - The request seeks all ‘communications’ between members of the PHARMAC senior leadership team, and in anticipation ...

Read more →

Alberta changes coverage of biologic drugs for people with Crohn's, diabetes, arthritis

12 December 2019 - The provincial government says will free up hundreds of millions of dollars in health funding during the ...

Read more →

Canadian study shows substantial savings possible with use of biosimilar filgrastim

12 December 2019 - During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar ...

Read more →

Alberta will force patients to switch from biologics to cheaper biosimilar medications

12 December 2019 - Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known ...

Read more →

Is it time to look beyond price with biosimilars?

5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...

Read more →